Positron emission tomography -computed tomography (PET-CT) is a highly sensitive clinical molecular imaging modality to study atherosclerotic plaque biology. Therefore, we sought to develop a new PET tracer, targeting vascular cell adhesion molecule (VCAM)-1 and validate it in a murine atherosclerotic model as a potential agent to detect atherosclerotic plaque inflammation.
Introduction
Many data support a crucial role of inflammation in the development and progression of atherosclerosis. 1, 2 Moreover, inflammation is involved in plaque destabilization and promotes thrombus formation. 1 Indeed, post-mortem studies, related to acute coronary events, reveal extensive infiltration of inflammatory cells in culprit lesions. 3 Vascular cell adhesion molecule-1 (VCAM-1), expressed on endothelial cells, plays an important role in the disease progression by attracting inflammatory cells (monocytes and T-lymphocytes) to the developing lesion. 4 In advanced lesions, VCAM-1 is also expressed at the level of neovessels and may reflect the ongoing inflammation within the plaque. 5 These properties make VCAM-1 an attractive target for the molecular imaging of inflammation in atherosclerosis. 6 Nanobodies (Nbs) are the smallest antigen-binding fragments (12) (13) (14) (15) that are derived from heavy-chain-only antibodies naturally occurring in camelids. 7 Their small size, nanomolar-range affinities, high specificity, and fast blood clearance make them appealing ligands for molecular imaging approaches 8 and this has been shown for several experimental disease models. 9 -16 Moreover, a Phase I clinical trial demonstrated the applicability of Nb-based tracers in humans. 17 Nuclear imaging techniques are the modalities of choice for molecular imaging because of their high sensitivity. We have recently reported the use of a technetium-99 m ( 99m Tc)-labelled anti-VCAM-1 Nb, referred to as cAbVCAM-1 -5, as strategy for the detection of inflamed atherosclerotic plaque with single-photon emission computed tomography (SPECT). 10 Yet, positron emission tomography (PET) is more appropriate for clinical use compared with SPECT because of its superior spatial resolution (3 -5 vs. 10 -15 mm), higher sensitivity (0.8 vs. 0.001%), and more accurate quantification. 18 Despite the advantages of PET, only a few clinical studies regarding molecular imaging of inflammation in atherosclerosis have been conducted. They are predominantly performed with tracers, e.g. 18 F-FDG, 15 11 C-PK11195, 19 or 18 F-FLT. 20 However, approaches using 18 F-FDG or 11 C-PK11195 are limited to the imaging of noncoronary atherosclerosis because of tracer uptake in the myocardium. 19, 21, 22 Therefore, the development of new robust PET tracers for imaging of biological processes implicated in highrisk atherosclerotic plaques is still warranted. In the current study, our objective is to generate a PET analogue of anti-VCAM-1 Nb for PET/CT imaging of atherosclerosis as a further step to clinical translation. Specifically, we describe (i) the radiolabeling of cAbVCAM-1 -5 with 18 F, (ii) the assessment of the functionality and specific targeting of this tracer, and (iii) in vivo PET/CT imaging of atherosclerotic lesions in apolipoproteindeficient (ApoE 2/2 ) mice.
Methods

F-Radiolabelling of cAbVCAM-1 -5 nanobody
Nanobodies recognizing both mouse and human VCAM-1 homologues have been described previously. Herein, a lead compound, cAbVCAM-1 -5, was selected as best candidate for further studies. ) and by reverse-phase high-performance liquid chromatography (RP-HPLC). For the latter, a polystyrene divinylbenzene copolymer reversed-phase column (PLRP-S 300 Å , 5 mm, 250/ 4 mm, Agilent) was used applying the following gradient (A: 0.1% TFA in water; B: 0.1% TFA in acetonitrile): 0 -5 min 25% B, 5 -7 min 25 -34% B, 7 -10 min 34 -100% B, and 10 -25 min 100% B at a flow rate of 1 mL min 21 . 10 (n ¼ 6) or with 70-fold molar excess of unlabelled cAbVCAM-1 -5 Nb (n ¼ 6). Mice were sacrificed at 3 h postinjection. Organs and tissues of interest were dissected, weighed and counted against a standard of known activity. Tissue or organ uptake was calculated and expressed as percentage of injected dose per gram (%ID/g), corrected for decay. Additional biodistribution data in C57Bl/6 mice at earlier time points are added as Supplementary data. To assess atherosclerotic lesion uptake, the aorta was dissected from aortic root to iliac bifurcation and was cut into 8 -10 segments. The segments were analysed on a microscope and a lesion-extension score was given according to plaque content: (Score 0) no lesion, (Score 1) lesion covering up to 30% of the segment, (Score 2) lesions covering 30 -75% of the segment, and (Score 3) lesions extending over the whole segment. Each segment was then weighed and counted for radioactivity in the gamma-counter. Lesion-to-blood and lesion-to-heart ratios were also determined. The 'lesion' and 'control lesion' were defined as the aorta segment with lesions extending over the whole segment length (Score 3) and aorta segment with no atherosclerosis development (Score 0), respectively.
PET/CT imaging
In vivo imaging was performed on a FLEX Triumph II triple-modality system (TriFoil Imaging, Chatsworth, CA 91311, USA). Four groups of animals were scanned (n ¼ 3 per group): C57Bl/6 control mice, ApoE One hundred and fifty minutes after tracer injection (4.68 + 2.45 MBq), the animals were placed under general anaesthesia using 2 -5% isoflurane, and a 30-min PET scan was acquired. The PET images were reconstructed into a 200 × 200 × 63 matrix by a 2D maximum likelihood expectation maximization (MLEM) algorithm (LabPET Version 1.12.1, TriFoil Imaging, Chatsworth, CA, USA) using 60 iterations and a voxel size of 0.5 × 0.5 × 1.175 mm 3 (x, y, z). Each PET scan was followed by a CT scan using the following acquisition parameters: 256 projections, detector pixel size 50 mm, tube voltage 75 kV, tube current 500 mA, and field of view 90 mm. CT images were analytically reconstructed using the filtered back projection reconstruction software of the scanner (Cobra Version 7.3.4, Exxim Computing Corporation, Pleasanton, CA, USA) into a 256 × 256 × 512 matrix with 200 mm isotropic voxel size. Each resultant CT image was inherently co-registered with the corresponding PET scan. Image analysis was performed using AMIDE imaging software. For quantification of the PET signal, regions of interest (ROIs) were drawn at the level of the ascending aorta and aortic arch (region with most extensive atherosclerotic lesion development) based on anatomical CT imaging. Mean standardized uptake values (SUV) were used to compare aortic uptake.
Statistical analysis
Data are expressed as mean + standard deviation. Variables were tested for homogeneity of variance by the Levene test. Comparisons between groups were performed using the one-way ANOVA tests with corrections for multiple comparisons. Correlations between variables were evaluated using the Spearman correlation coefficient. A P-value of ,0.05 was considered significant. Statistical analysis was done using SPSS Statistics software (version 22.0.0, IBM Company, Chicago, IL, USA).
Results
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PET/CT imaging
In accordance with the ex vivo biodistribution data, PET/CT images revealed for both 18 F-labelled Nbs high signals in the kidneys and the bladder. Signals in other organs and tissues were very low. Analysis of transversal, coronal, and sagittal PET/CT images showed accumulation of [ 18 F]FB-cAbVCAM-1-5 at the level of ascending aorta and aortic arch of ApoE 2/2 mice, the region where most of the segments are scored as 3, while only background signals were observed for the control groups ( Figure 4A) . Hence, quantification of the mean SUV in this region revealed this difference was significant (P , 0.0001) ( Figure 4B ). Lesions along the abdominal aorta could not be identified due to the high renal activity.
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Discussion
In the present study, we have described the development and validation of a new PET tracer specific for VCAM-1, and we demonstrated the non-invasive PET/CT imaging of VCAM-1 expression in atherosclerotic plaques in a murine model. This may represent an attractive tool for clinical translation of imaging inflamed atherosclerotic plaques in patients. Recently, we have reported the selection of the lead compound cAbVCAM-1 -5 with nanomolar affinity for mouse and human VCAM-1 based on the screening of 10 Nbs derived from heavy-chain-only antibodies raised in an immunized dromedary. This compound was labelled with 99m Tc for SPECT imaging of atherosclerotic lesions in ApoE 2/2 mice and it was shown that the uptake of 99m Tc-cAbVCAM-1-5 correlated with the level of VCAM-1 expression in these lesions. 11 Moreover, SPECT/CT imaging with this tracer was used to monitor the anti-inflammatory effects of statins. 11 In the current study, cAbVCAM-1 -5 Nb was radiolabelled with 18 F, often referred to as the 'radionuclide of choice' for PET imaging. Compared with other imaging modalities, PET is currently the preferred clinical modality because it is the most sensitive and quantitative clinical molecular imaging technology. This feature is particularly important for the detection of molecular markers of atherosclerotic plaques where targets are commonly small and sparse. Essential characteristics of a radiotracer for clinical translation are purity and stability, high specificity and affinity for the target, and fast blood clearance to reach high target-to-background ratios. 18 Targeting of vascular cell adhesion molecule-1 cortex by a mechanism that is at least partially mediated by the megalin-receptor system. 24 Remarkably, the kidney retention of We speculate that these differences are partly due to different specific activities of the tracers next to different biophysical and chemical properties of the radiolabelled compounds in vivo. Nevertheless, comparable lesion-to-blood and lesion-to-heart ratios were observed.
The abundant presence of macrophages is a hallmark feature of potential vulnerable plaques. 25 Over the past decade, there has been increasing interest in the development of molecular imaging methods capable of imaging the extent of plaque inflammation that could potentially provide powerful predictive information on future cardiovascular events. 26 VCAM-1 expression has been most preferentially studied because of its function to recruit inflammatory cells to the arterial intima and because its expression pattern could reflect the degree of plaque inflammation. 6 F-4V, for PET/CT imaging of VCAM-1 expression. Comparable results with the present study were obtained in terms of lesion-to-normal vessels, lesion-to-blood, and lesion-to-myocardium ratios.
Besides the anti-VCAM-1 Nb presented in this study, many other Nb-based tracers have been developed and validated in preclinical models for the imaging of a variety of specific disease-related biomarkers. 32 They have been successfully labelled with different radio- Ga-labelled HER2-specific Nb as PET tracer to screen breast cancer patients for HER2 expression. 17 Moreover, preparations for a Phase I clinical trial with cAbVCAM-1 -5 Nb have already been initiated as the current tracer is being produced complying with Good Manufacturing Practice (GMP) requirements. In clinical research 18 F-FDG has been widely used for imaging of plaque inflammation in carotid lesions. 37 However, coronary artery imaging remains extremely challenging due to high myocardial background that is generally greater than any signal originating from a plaque. The low myocardial uptake of [ 18 F]FB-cAbVCAM-1-5 Nb with a high lesion-to-myocardium ratio renders it a promising tracer for potential molecular imaging of coronary atherosclerosis in patients. Indeed, the feasibility of coronary molecular imaging in patients using PET/CT has already been shown using 18 F-sodium fluoride ( 18 F-NaF) as a tracer of active microcalcification in atherosclerotic plaques 38 or 18 F-FLT, a thymine analogue accumulating in proliferating cells. 20 However, further studies are needed to evaluate the impact of these findings on patient management and treatment.
Study limitations
The present approach of PET/CT imaging of VCAM-1 expression requests some considerations. The majority of thrombotic events in culprit lesions are caused by plaque rupture. 25 These plaques
show typically intensive infiltration of inflammatory cells. However, Figure 3 Uptake in aorta segments according to the lesion-extension score. Aortic uptake in ApoE 20-30% of coronary thrombi evolve from plaques that do not have a large lipid core or significant inflammation but have superficial endothelial erosions. 3 This subset of high-risk plaques might be missed by the current method.
In this study, we were able to visualize plaque inflammation in a murine model of atherosclerosis. However, atherosclerotic lesions of murine models differ from human pathology. [ 
Conclusion
The present study demonstrates a sensitive and specific method for non-invasive PET/CT imaging of VCAM-1 expression within atherosclerotic lesions, which may provide important information to characterize atherosclerotic plaque inflammation. This preclinical validation study holds the potential to be translated in patients. Further clinical studies are needed to put this technology a step forward in our quest for imaging potential vulnerable plaques.
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